Antibody-Drug Conjugates: The Last Decade
An armed antibody (antibody-drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylot...
Saved in:
Main Authors: | Nicolas Joubert (Author), Alain Beck (Author), Charles Dumontet (Author), Caroline Denevault-Sabourin (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment-Drug Conjugates (FDCs)
by: Louis Jolivet, et al.
Published: (2022) -
Internalization of Foldamer-Based DNA Mimics through a Site-Specific Antibody Conjugate to Target HER2-Positive Cancer Cells
by: Valentina Corvaglia, et al.
Published: (2021) -
Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform
by: Louise Conilh, et al.
Published: (2021) -
Antibody drug conjugates in the clinic
by: Edidiong Udofa, et al.
Published: (2024) -
Advances in dialysis in the last decade
by: Olynka Vega-Vega, et al.
Published: (2023)